Prostaglandin E2 (PGE 2 ), a major cyclooxygenase (COX) metabolite, plays important roles in tumor biology. We studied the role of EP2, a receptor for PGE 2 , in tumor angiogenesis using EP2 knockout mice. We found that deletion of the EP2 receptor impaired tumor angiogenesis and this finding was confirmed by an in vivo corneal angiogenesis model and an ex vivo aortic ring assay. To further characterize the cellular mechanisms of the EP2 receptor in angiogenesis, we isolated primary pulmonary endothelial cells (ECs) from wild-type (wt) and EP2 À/À mice and observed that EP2 À/À ECs exhibited defects in vascular branch formation when compared to wt ECs. In addition, EP2 À/À ECs showed impaired cell motility on collagen-coated surface and they responded poorly to PGE 2 -induced cell migration compared to control cells. However, no difference in cell proliferation was observed between the EP2 À/À and wt Ecs. In addition, EP2 À/À ECs were more susceptible to apoptosis than wt cells under growth factor depletion conditions. Collectively, our data demonstrate that EP2 signaling in endothelium directly regulates tumor angiogenesis by contributing to cell survival and endothelial cell motility. Moreover, our finding suggests that EP2 is a major receptor in PGE 2 -mediated cell motility in ECs.
Introduction
Tumor angiogenesis is essential for tumors to grow and progress; therefore, targeting this process offers a promising approach for cancer therapy. Angiogenesis is a multi-step process that consists of endothelial cell proliferation, cell migration, vascular tubule formation and cell survival. A variety of mediators regulate angiogenesis, including growth factors and their cell surface receptors, matrix-degrading enzymes (e.g. matrix metalloproteinases) and adhesion receptors of the integrin family (Klagsbrun and Moses, 1999; Kerbel, 2000; Yancopoulos et al., 2000) .
Prostaglandin E2 (PGE 2 ) is a major metabolite of cyclooxygenase-1 and -2 (COX-1 and COX-2). Overexpression of COX-2 and of PGE 2 has been observed in colorectal cancer, lung cancer and prostate cancer (Eberhart et al., 1994; Kargman et al., 1995; Sano et al., 1995; Dubois et al., 1998; Hida et al., 1998; Chang et al., 2004) . PGE 2 exerts its function through cell surface receptors, which consist of four receptor subtypes, designated as EP1, EP2, EP3 and EP4. The differential expression pattern of these receptors on cell surface mediates the diverse biological functions of PGE 2 in different cell types (Narumiya et al., 1999; Breyer et al., 2001; Tilley et al., 2001) . Recently, it has been shown that activation of EP2 via PGE 2 contributes to mammary hyperplasia by enhancing the expression of amphiregulin, a potent mammary epithelial cell growth factor (Chang et al., 2005) . Moreover, studies have shown that COX-2 and PGE 2 regulate tumor angiogenesis (Tsujii et al., 1998; Rozic et al., 2001; Sonoshita et al., 2001; Seno et al., 2002; Kuwano et al., 2004) . Homozygous deletion of the gene encoding EP2 decreases the number and size of intestinal polyps in Apc D716 mice, a mouse model for human familial adenomatous polyposis (Sonoshita et al., 2001; Seno et al., 2002) . These tumors exhibit reduced tumor vascular density, suggesting that the reduced tumor growth in the EP2 knockout mice is owing to the inhibition of tumor angiogenesis. Despite increasing evidence indicating a role for the EP2 receptor in angiogenesis, the precise role and the molecular mechanisms of EP2 signaling in endothelium and/or tumor angiogenesis still need to be elucidated. In this study, we report that the EP2 receptor regulates tumor angiogenesis by contributing to endothelial cell survival and cell motility. Our finding provides the first evidence that EP2 signaling in endothelium directly regulates angiogenesis and it suggests that the EP2 receptor may be a potential therapeutic target for tumor treatment.
Results

Tumor angiogenesis and tumor growth are impaired in EP2
À/À mice To study the role of EP2 in tumor angiogenesis, we used a vascular tumor window model (Lin et al., 1997) . This model allows direct visualization and analysis of tumor angiogenesis in live animals. A small piece (B0.1 mm 3 ) of 4T1-derived tumor harvested from a wild-type (wt) donor mouse was implanted in the cutaneous window chamber established in EP2 À/À mice and wt littermates. Tumor angiogenesis in live animals was examined and recorded under microscopy at various time points, and quantified by measuring the tumor vascular length density. Vascular length density measures both vessel density and vessel size, thereby providing a true measurement of tumor angiogenesis. Ten days after implantation, tumor tissues were harvested and tumor volume and angiogenesis were analysed. We observed a significant reduction of tumor angiogenesis in EP2 À/À mice, with an approximately 50% decrease of tumor vascular length density compared to the wt mice ( Figure  1a -e), accompanied by a significant reduction of tumor growth (Figure 1f ). Tumor sections were stained with an antibody against CD31 and the CD31-positive vessels were counted in randomly selected fields. A significantly reduced number of positive vessels were observed in tumors from EP2 À/À mice compared to their wt counterparts (Figure 1g-i) . Collectively, these data support a role for EP2 signaling in tumor angiogenesis.
Angiogenesis is impaired in EP2
À/À mice in vivo and ex vivo As tumor angiogenesis is impaired in EP2
À/À mice, we examined the role of EP2 signaling in adult angiogenesis using a corneal micropocket assay (Lin et al., 1997) . The corneal assay is simple and can measure the angiogenic response to a single angiogenic agent in contrast to tumor angiogenesis where different angiogenic agents are involved. Corneal angiogenesis occurred between day 4 and 7 after the implantation of hydron pellets containing 5 ng of basic fibroblast growth factor (bFGF). At day 7, we intravenously injected Indian ink for visualization of the blood vessels. The mouse corneas were harvested and mounted on a slide for examination. Vascular response was quantified by calculating the neovascular areas in corneas. A significant reduction of corneal angiogenesis was observed in EP2
À/À mice compared to the wt littermates (Figure 2 ), thus supporting a role of EP2 signaling in adult angiogenesis.
To further confirm these in vivo findings, we used an aortic ring model that recapitulates the entire process of angiogenesis in vitro. Segments of mouse aorta from either wt or EP2 À/À mice were embedded in fibrin gels and overlaid with endothelial growth media (EGM) endothelial cell culture media. Seven days after incubation, we observed an abundant development of vascular sprouts from the aortic rings of wt mice (Figure 3a and c) , compared to the fewer vascular sprouts detected in the rings of EP2 À/À mice (Figure 3b and c) . Altogether, these data suggest that EP2 signaling in endothelium regulates angiogenesis.
Deletion of EP2 in endothelial cells impairs vascular branch formation in a 3-D gel assay To assess the direct role of EP2 signaling in endothelium in angiogenesis, we isolated microvascular endothelial cells (ECs) from lungs of wt mice and EP2 À/À mice. We analysed the effects of EP2 on vascular sprouting in a three-dimensional (3-D) collagen gel assay. Lung microvascular ECs from both wt and EP2 À/À mice were plated on collagen I alone or a combination of collagens I and IV. Endothelial cell branching formation was evaluated 48 h after plating (Figure 4a-e) . The total number of vascular branches was counted in eight randomly selected areas in each well. We observed almost 50% reduction in the number of branching structures in EP2 À/À ECs compared to wt ECs ( Figure 4e ). Moreover, this difference was independent from the substrate on which the ECs were plated. This finding is in agreement with the in vivo data that deletion of EP2 in ECs leads to impaired tumor angiogenesis and corneal angiogenesis.
To determine whether the defect in branching was indeed owing to loss of EP2 expression, we verified the expression of EP2 receptor in primary ECs by reverse transcription-polymerase chain reaction (RT-PCR). Total RNA was isolated from freshly isolated wt and EP2 À/À ECs or from a murine endothelial cell line (MS-1) used as positive control. As shown in Figure 4f , although the EP2 transcript was detected in MS-1 and wt pulmonary ECs, no detectable EP2 expression was evident in ECs isolated from the EP2 À/À mice ( Figure 4f ). Together, these results provide the first evidence demonstrating that EP2 signaling in endothelium directly regulates angiogenesis.
Deletion of EP2 in ECs has no effects on DNA synthesis Angiogenesis is a multi-step process that includes endothelial cell proliferation, migration and survival. Therefore, we determined whether loss of EP2 signaling in ECs might affect one or more of these functions. Wt and EP2
À/À ECs were cultured on wells coated with a mixture of collagens I and IV. After 3 days, DNA synthesis was measured by 3 H-thymidine incorporation. No significant differences in DNA synthesis were observed between wt and EP2 À/À ECs ( Figure 5 ), suggesting that the EP2 receptor does not regulate endothelial cell proliferation.
Deletion of EP2 impairs endothelial cell migration
We next examined the role of EP2 signaling in endothelial cell migration using a Transwell assay. We observed a significant reduction in basal cell migration toward collagen-coated wells in EP2 À/À ECs when compared to their wt counterparts ( Figure 6a , 'none'). As no chemotactic/angiogenic agent was added to the bottom of the wells, this result implies a physiological role for the EP2 receptor in the control of endothelial À/À mice (c and d) with implantation of a small piece of 4T1-derived tumor. Tumor window photos were taken 10 days after tumor implantation (a-d). Scale bar, 1 mm. Tumor vascular length density (e) and tumor volume (f) were calculated as described in Materials and methods. Tumor sections harvested from wt (g) and EP2
À/À (h) mice were processed for CD31 immunostaining. CD31-positive blood vessels were counted in 10 randomly selected high-power fields under microscopy (i). N ¼ 7 for both wt and EP2 À/À mice.
EP2 receptor regulates tumor angiogenesis M Kamiyama et al addition, we determine the ability of vascular endothelial growth factor (VEGF), a well-know angiogenic factor, to stimulate migration of wt and EP2 À/À cells. Deletion of the EP2 receptor significantly impaired cell migration in response to PGE 2 stimulation compared to wt cells (Figure 6a , 'PGE 2 '). Despite the fact that VEGF-simulated migration of both wt and EP2 À/À ECs, reduced migration was still observed in the latter group ( Figure 6a , 'VEGF'). This result indicates that both EP2-dependent (i.e. PGE 2 ) and EP2-independent (i.e. VEGF or bFGF) signals are responsible for endothelial cell migration. Moreover, the data obtained with VEGF parallels our finding that in vivo angiogenesis is reduced in EP2
À/À mice in response to bFGF stimulation ( Figure 2 ).
To further confirm the specific role of EP2 in EC migration, we treated the wt and EP2-null lung ECs with an EP2-receptor-selective agonist, Butaprost, using the same Transwell assay as described above. Although wt ECs exhibited a significant increase in cell migration in response to the Butaprost treatment (Figure 6b ), which is comparable to the levels of cell migration in the PGE2-treated group (Figure 6a ), in contrast, EP2-null cells failed to exhibit significant response (Figure 6b ). These data clearly suggest that EP2 is a major receptor in PGE 2 -mediated cell motility in ECs.
Deletion of EP2 enhances endothelial cell apoptosis under serum starvation conditions Endothelial cell survival is an integral step in angiogenesis. Therefore, we examined the role of EP2 in endothelial cell survival. Primary ECs from wt and EP2 À/À mice were seeded on collagen-coated dishes in the presence of endothelial cell growth medium for 4 h to allow the cells to attach to the plates. The cells were then incubated in serum-free medium and live cells were evaluated 24 h after starvation. A significant reduction in the number of EP2 À/À live ECs was observed as compared to that of wt cells (Figure 7a ). To confirm the reduction in cell survival was owing to apoptosis, terminal deoxynucleotidyl transferase nick-end labeling Angiogenesis is impaired in EP2 À/À mice. A hydron pellet containing 5 ng/pellet bFGF was implanted in a surgically created micropocket on the cornea of EP2 À/À mice (b) and wt control mice (a). Seven days post pellet implantation, animals were killed and the corneas were perfused with India ink and then excised to obtain the record of the vascular pattern of growth. Representative photos were presented. Angiogenic response was quantified by measuring the neovascular area in the corneas (c). Seven pairs of animals were used in the study. Circled P indicates the pellet implantation site in the mouse cornea.
(TUNEL) staining was performed. As shown in Figure 7b , there were more EP2 À/À apoptotic cells than controls (Po0.01). These data suggest that increased endothelial cell apoptosis in addition to defects in cell motility could account for the impaired vascular formation in EP2 À/À mice.
Discussion
Overexpression of COX-2 and overproduction of PGE 2 have been shown to regulate tumor angiogenesis, and the EP2 receptor has been implicated in this process Tsujii et al., 1998; Rozic et al., 2001; Sonoshita et al., 2001; Dormond et al., 2002; Seno et al., 2002) . However, the molecular mechanisms remain to be elucidated and, most importantly, it is not clear whether EP2 signaling in endothelium directly contributes to tumor angiogenesis. In this study, we investigated the function and the molecular mechanisms of EP2 signaling in tumor angiogenesis using EP2 deficient mice. Our data show that ECs express the EP2 receptor and inactivation of EP2 function leads to impaired physiological as well as pathological angiogenesis. This impairment is owing to a reduced basal as well as PGE 2 -and Butaprost-induced migration in EP2 À/À ECs. Moreover, following serum deprivation, EP2 À/À ECs undergo more apoptosis than wt cells and this correlates with increased activation of extracellular signal-regulated kinase (ERK) (data not shown). Taken together, our data provide direct evidence that EP2 signaling in ECs regulates endothelial cell motility and survival, thus contributing to tumor angiogenesis in vivo.
In an earlier study, we showed that EP2 À/À mice exhibited significantly attenuated tumor growth and longer survival time when challenged with MC26 and LLC tumor cells as compared to the wt littermates (Yang et al., 2003) . We identified a series of cancerassociated immune deficiency and dendritic cell abnormalities in the EP2 À/À mice compared to their wt counterparts, which may contribute to the attenuated tumor growth in the null mice. However, we did not observed any significant difference in tumor vessel density measured by the CD31 staining on tumor sections between these two groups. In this study, we thoroughly examined the role of EP2 receptor in tumor angiogenesis. We used animal models coupled with a non-invasive in vivo imaging approach to examine the kinetics of tumor angiogenesis. We provide in vivo, ex vivo and in vitro evidence demonstrating a role of EP2 signaling in angiogenesis through the regulation of endothelial cell motility and cell survival. One possible explanation for our previous finding is that vessel density measured by the CD31 staining is a snap shot of a dynamic tumor angiogenesis process. Vessel density measured by CD31 staining cannot distinguish between large and small vessels, and therefore is not a direct measurement of tumor angiogenesis, unlike the assays presented in the present study.
Non-steroidal anti-inflammatory drugs (NSAIDs), which act by inhibiting COX activity and the synthesis of prostaglandins, inhibit tumor development and tumor progression Williams et al., 1999) . One of the anti-tumor effects of NSAIDs is inhibition of tumor angiogenesis through direct effects on ECs (Dormond et al., 2002) . PGE 2 , a major metabolite of both COX-1 and -2, promotes endothelial cell adhesion and spreading through PKA-dependent signaling (Dormond et al., 2002) . PGE 2 also regulates cell motility in different cell types, including ECs (Dormond et al., 2001; Hernandez et al., 2001; Jiang et al., 2004) . In this study, we observed that inactivation of EP2 signaling impaired vascular branching formation and cell motility, which is in agreement with the findings involving PGE 2 and NSAIDs (Dormond et al., 2002) . In addition, our data identify the EP2 receptor as a major receptor that regulates PGE 2 -mediated endothelial cell motility.
In this study, we did not observe any difference in cell adhesion and/or spreading on different extracellular matrix components between EP2
À/À and wt ECs (data Ring-like structure formation was followed over time and representative images taken 48 h after plating are shown. The number of vascular branches were evaluated at 48 h by counting eight randomly selected microscopic fields with duplicate samples (e) Po0.001. Total RNA was isolated from murine MS1 cells and freshly isolated wt and EP2 À/À ECs, and RT-PCR analysis was performed using specific primers for EP2 (f). Housekeeping gene b-actin was used as a sample control.
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M Kamiyama et al not shown), in contrast with the finding that treatment with PGE 2 increases cell adhesion and spreading in ECs (Dormond et al., 2002) . This difference could be explained by the existence of multiple receptors on cell surfaces for PGE 2 , which could compensate or act instead of the EP2 receptor. In this context, it has been shown that human umbilical vein endothelial cells express both EP2 and EP4 (Dormond et al., 2002) , and EP3-null mice show decreased tumor growth and angiogenesis (Amano et al., 2003) . Moreover, deletion of EP1 and EP4 inhibits tumor development (Watanabe et al., 1999; Mutoh et al., 2002) , clearly suggesting that different EP receptors may mediate specific aspects of tumor angiogenesis. Vascular endothelial cell survival is essential for the formation as well as function of blood vessels. In addition to impaired cell motility, we observed enhanced cell apoptosis of EP2 À/À ECs under serum-starved conditions compared to wt cells. Therefore, impaired tumor angiogenesis of EP2 mice could be explained by both impaired endothelial cell motility and enhanced cell death. ERK is known to mediate COX-2 expression in several cell types in response to various stimuli (Husain et al., 2001) . ERK activity also regulates COX-2-selective NSAID-induced apoptosis in colorectal carcinoma cells (Elder et al., 2002) . Treatment of HT29 colon cancer cells with NS-398, a COX-2-specific inhibitor, leads to the activation of ERK, but not p38 and c-Jun NH 2 -terminal kinase (Elder et al., 2002) and NS-398-induced ERK activation precedes and accompanies an increase in apoptosis. In addition, inhibiting ERK activation protects the cells from NS-398-induced apoptosis, indicating that sustained ERK activation in response to the COX-2 inhibition plays a proapoptotic role (Elder et al., 2002) . In agreement with these findings, we observed that deletion of EP2 in ECs enhances cell apoptosis. Interestingly, the enhanced apoptosis in EP2 À/À cells correlates to elevated activation of ERK (data not shown), suggesting that sustained activation of ERK in EP2 À/À ECs may be responsible for cell apoptosis. Current efforts are directed toward understanding the mechanisms of EP2 signaling in ERK activation and apoptosis.
Finally, it has been shown that EP2 and VEGF receptor can cooperate in regulating endothelial cell motility (Bradbury et al., 2005; Chang et al., 2005) . In this regard, we show here that stimulation with PGE 2 or angiogenic factors (i.e. VEGF or bFGF) is not sufficient to enhance EP2 À/À endothelial cell migration to the levels observed in stimulated wt cells. This result suggests that both EP2-dependent and EP2-independent pathways play a relevant role in regulating endothelial cell migration.
In summary, we demonstrate that EP2 signaling in ECs regulates tumor angiogenesis through the regulation of endothelial cell motility and survival, but not cell À/À lung ECs were added to Transwells coated with collagen and allowed to migrate toward medium with or without PGE 2 (1 mM) or VEGF (25 ng/ml), respectively (a), and an EP2-selective agonist Butaprost (10 mM) (b). Migrating cells were counted 4 h after cell plating (a). Eight randomly selected high-power fields were counted for each well. Columns represent the means of three independent experiments; bars represent s.e. Each experiment was performed in triplicate.
proliferation. The EP2 receptor is the major EP receptor involved in PGE2-mediated endothelial cell motility. This study thus identifies the EP2 receptor as a potential target for anti-angiogenic therapy.
Materials and methods
Reagents
Human recombinant VEGF and human recombinant bFGF were obtained from the National Cancer Institute (Rockville, MD, USA), and human collagen IV and bovine collagen I were obtained from Sigma (St Louis, MO, USA). PGE 2 and Butaprost were purchased from Calbiochem, San Diego, CA, USA and Cayman, Ann Arbor, MI, USA, respectively. 4T1 murine mammary carcinoma cells and MS-1 murine ECs were obtained from ATCC (Manassas, VA, USA). The cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS).
Mice
EP2
À/À mice were generated as described (Kennedy et al., 1999) and backcrossed for 10 generation produce a pure Balb/c background strain. Seven to nine weeks old females were used for the tumor study and corneal assay. Age-and sex-matched mice were used as donors for isolation of primary pulmonary microvascular ECs. The mice were housed in pathogen-free units at the Vanderbilt University School of Medicine in compliance with Institution Animal Care and Use Committee (IACUC) regulations.
Tumor window chamber model
The in vivo tumor vascular window model was performed as described previously, involving a metal frame applied to the back skin fold of mice (Lin et al., 1997) . Briefly, a 0.8 cm diameter hole was dissected in one side of the epithelial surface of the dorsal skin flap. The underlying tissue was dissected away until a fascial plane with associated vasculature remained. A small piece (0.1 mm 3 ) of 4T1-derived tumor was put on the fascial plane, saline solution was added, and the chamber was then sealed with a glass coverslip to form a semitransparent chamber. Tumor window chambers (200 mm thick) were photographed daily using an BX51 Olympus microscope for vascular length density measurement.
Measurement of tumor volume and tumor vascular length density
To obtain the tumor size, hematoxylin and eoson-stained sections representing the largest cross-sectional area of each tumor were photographed and the thickness (t) and the diameter (d) of tumors were measured from the photographs. Tumor volumes, which were assumed to approximate a flat cylinder in shape, were calculated using the formula:
Tumor vascular length density as an indicator of tumor vasculature was measured from photographs of 10-day-old tumors within the window chamber using a previously described method (Lin et al., 1997) . Three to five areas inside the tumor were randomly selected for measurement, and the vascular length density in mm/mm 3 was calculated.
Mouse cornea micropocket assay
The assay was performed as described previously (Lin et al., 1997) . In brief, a hydron pellet containing 5 ng of bFGF was implanted into a surgically created micropocket, 0.5-1 mm from the limbus, in age-and sex-matched EP2 À/À mice and wt controls. Seven days after pellet implantation, mice were perfused intra-ventrically with India ink. The corneas were dissected and examined under an Olympus Provis Microscopy connected to a digital imager. Images were analysed using NIH imaging software to determine the circumference area of neovascularization as an index of corneal angiogenesis.
Aortic ring assay
The assay was carried out as described previously (Huang et al., 1999) . Briefly, thoracic aortas were excised from 6-weekold mice. Clotted blood inside the aorta was flushed with media and periadventitial fibroadipose tissue was removed. Aortas were then cut into small cross-sectional pieces approximately 0.3 mm in length. Pieces of aorta were placed into 48-well plates and overlaid with 150 ml of a freshly prepared fibrinogen solution (3 mg/ml). The fibrin gel was polymerized by the addition of 15 ml of thrombin (1 U/ml; Sigma) for 1-2 h at room temperature followed by the addition of 0.5 ml of EGM (Clonetics, Walkersville, MD, USA). The culture was maintained at 371C with 5% CO 2 and the medium was replaced every other day. Rings were examined grossly each day and digital images were obtained for quantitative analysis of endothelial sprouts at day 7. The number of sprouts was determined by counting the number of tube-like structures originating directly from the aortic ring (exclusive of branches).
Isolation of primary lung ECs and cell culture
Murine pulmonary microvascular ECs were isolated as described (Pozzi et al., 2000) . Briefly, mice were anesthetized and the lung vasculature was perfused with phosphatebuffered saline (PBS)/2 mM ethylenediaminetetraacetic acid (EDTA) followed by 0.25% trypsin/2 mM EDTA via the right ventricle. Heart and lungs were removed en block and incubated at 371C for 15 min. The visceral pleura were then trimmed away, and the perfusion with trypsin was repeated. After neutralization with DMEM complete medium, perfused cells were centrifuged at 2000 r.p.m. for 10 min and placed in six-well dishes pre-coated with 0.2% gelatin. Primary ECs that were 93% pure by immunostaining with an anti-CD31 were grown in EGM-2-MV (Clonetics) containing 5% FBS.
Vascular branch formation assay
To evaluate endothelial cell branching, ECs were plated on 3-D collagen gels. Bovine collagen I at 2 mg/ml and human collagen IV at 200 mg/ml were mixed with Â 10 DMEM and 1 M N-2-hydroxyeethyl-piperazine-N-2-ethanesulfonic acid at the ratio 8:1:1:1. Collagen gel (250 ml) was added to 24-well plates and allowed to polymerize at 371C for 2 h. ECs were prepared from subconfluent cultures in complete media. A total of 2.5 Â 10 4 cells were added to each well and incubated at 371C. The quantity of the vascular branches was evaluated 48-72 h after cell plating by counting 8 randomly chosen fields from duplicate wells.
RT-PCR
Total RNA from cells was extracted using the RNAeasy kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. For RT-PCR, 10 mg of total RNA were reverse transcribed to first strand cDNA using oligodeoxythymidylic acid primers and the SuperScript preamplification system (Invitrogen, Carlsbad, CA, USA). The cDNAs of the mouse EP2 receptor and the housekeeping gene b-actin were amplified from single-stranded cDNA by PCR using TaqDNA Polymerase and 0.4 mM of each primer. The EP2 PCR primers were as follows: forward primer, 5 0 -TGCTGCCTGTCATC TAT; and reverse primer, 5 0 -TGAGGATAACGCTGATGT. The PCR product of EP2 is 201 bp. The mouse b-actin PCR primers were as follows: forward, 5 0 -GACAACGGCTCCGG CATGTGC; and reverse primer, 5 0 -TGGCTGGGGTGT TGAAGGTC. The PCR product of b-actin is 363 bp.
Cell proliferation assay A total of 1 Â 10 4 primary ECs were grown in EGM-2-MV containing 5% FBS on 96-well plates coated with 20 mg/ml bovine collagen I, 10 mg/ml human collagen IV or a mixture of collagens I and IV. Cells were cultured for 2 days followed by pulse labeling with 3 H-thymidine (1 mCi/well) for an additional 24 h as described previously (Pozzi et al., 2000) . The cells then were harvested, and trichloroacetic acid-precipitated lysates were measured with a b-counter.
Cell migration assay
Polyvinylpyrrolidone-free polycarbonate Transwells, with 8 mm pores (Costar, Acton, MA, USA), were pre-coated with a mixture of collagen I (20 mg/ml) and collagen IV (10 mg/ml) overnight at 41C. The filters were subsequently blocked with 3% BSA in PBS to inhibit nonspecific migration. The lower wells of the chamber were filled with medium containing 0.1% BSA. Endothelial cell suspensions were prepared from subconfluent cultures in serum-free medium containing 0.1% BSA. A total of 5 Â 10 4 cells were added to the upper chamber and then incubated for 4 h at 371C.
The cells were incubated for 4 h at 371C. At the end of the incubation, non-migrating cells on top of the filter were removed by wiping, and the filters were fixed in 3% formaldehyde in PBS. Migrating cells were stained with 1% crystal violet and counted under microscopy. The chemotaxis assay was performed as above, with the exception that either PGE 2 -(1 mM), or VEGF-(25 ng/ml), or EP2-selective agonist Butaprost (10 mM) was added into the bottom chamber, respectively.
Detection of endothelial cell survival ECs from wt and EP2
À/À mice were seeded on collagen-coated wells and maintained in EGM-2-MV medium. Upon reaching 75% confluence, the cells were washed once with PBS and then incubated at 371C for 24 h in serum-free medium. The cells were stained with trypan blue and live cells were counted under microscopy. In addition, cells were cultured on glass slide chambers (Nunc, Rochester, NY, USA) under the same condition as described above. The cells were harvested 24 h after serum starvation and genomic DNA fragmentation was determined by the TUNEL assay following the manufacture's instructions (Chemicon, Temecula, CA, USA).
Statistics
Results are reported as mean7s.e. for each group. A twotailed Student's t-test was used to analyse statistical differences between EP2 knockout mice and wt control mice. Differences were considered statistically significant when Po0.05.
